Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging

European Journal of Pharmacology

Volumn 482, Issue 1-3, 2003, Pages 319-324

  Tigani, Bruno ^a   Di Padova, Franco ^a   Zurbrügg, Stefan ^a   Schaeublin, Elisabeth ^a   Revesz, Laszlo ^a   Fozard, John R ^a   Beckmann, Nicolau ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allergen; Allergic pulmonary inflammation; Asthma; Glucocorticosteroid; Lung; Magnetic resonance imaging (MRI); Mitogen activated protein kinase inhibitor; Oedema; Oedema resolution

Indexed keywords

4 (4 FLUOROPHENYL) 2 (1 METHYLPIPERIDIN 4 YL) 5 [2 (1 PHENYLETHYL)AMINO 4 PYRIDINYL]THIAZOLE FUMARATE; ANTIGEN; CORTICOSTEROID; GLUCOCORTICOID; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 BETA2; MOMETASONE FUROATE; OVALBUMIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; EDEMA; IMAGE ANALYSIS; INHIBITION KINETICS; LUNG; LUNG LAVAGE; MALE; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PRIORITY JOURNAL; PROVOCATION TEST; RAT; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; SIGNAL DETECTION; SIGNAL TRANSDUCTION; TIME;

EID: 0345599925     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.052     Document Type: Article

References (17)

1. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279:1996;1453-1461.
2. Beckmann N., Tigani B., Ekatodramis D., Borer R., Mazzoni L., Fozard J.R. Pulmonary edema induced by allergen challenge in the rat: noninvasive assessment by magnetic resonance imaging. Magn. Reson. Med. 45:2001;88-95.
3. Elwood W., Lotvall J.O., Barnes P.J., Chung K.F. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats. J. Allergy Clin. Immunol. 88:1991;951-960.
4. Escott K.J., Belvisi M.G., Birell M.A., Webber S.E., Foster M.L., Sargent C.A. Effect of the p38 kinase inhibitor, SB203580, on allergic airway inflammation in the rat. Br. J. Pharmacol. 131:2000;173-176.
5. Hannon J.P., Tigani B., Williams I., Mazzoni L., Fozard J.R. Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br. J. Pharmacol. 132:2001;1509-1523.
6. Herlaar E., Brown Z. p38 MAPK signaling cascades in inflammatory disease. Mol. Med. Today. 5:1999;439-447.
7. Inman M.D., Watson R.M., Rerecich T., Gauvreau G.M., Lutsky B.N., Stryszak P., O'Byrne P.M. Dose dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am. J. Respir. Crit. Care Med. 164:2001;569-574.
8. Jackson J.R., Bolognese M.A., Hillegass L., Kassis S., Adams J., Griswold D.E., Winkler J.D. Pharmacological effects of SB220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284:1998;687-692.
9. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landvatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., Young P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 372:1994;739-746.
10. Lee J.C., Kassis S., Kumar S., Badger A., Adams J.L. P38 Mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol. Ther. 82:1999;389-397.
11. New L., Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc. Med. 8:1998;220-229.
12. Pearson G., Robinson F., Gibson T.B., Xu B.-E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22:2001;153-183.
13. Schafer P.H., Wadsworth S.A., Wang L., Siekierka J.J. p38α Mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+ CD45RO+ T cells and Th2 effector cells. J. Immunol. 162:1999;7110-7119.
14. Tigani B., Schaeublin E., Sugar R., Jackson A.D., Fozard J.R., Beckmann N. Pulmonary inflammation monitored non-invasively by MRI in freely breathing rat. Biochem. Biophys. Res. Commun. 292:2002;216-221.
15. Tigani B., Cannet C., Zurbrügg S., Schaeublin E., Mazzoni L., Fozard J.R., Beckmann N. Resolution of the oedema associated with allergic pulmonary inflammation in rats. Br. J. Pharmacol. 140:2003;239-246.
16. Underwood S.L., Raeburn D., Lawrence C., Foster M., Webber S., Karlsson J.A. RPR 106541, a novel, airways-selective glucocorticoid: effects against antigen-induced CD4+ T lymphocyte accumulation and cytokine gene expression in the Brown Norway rat lung. Br. J. Pharmacol. 122:1997;439-446.
17. Underwood D.C., Osborn R.R., Kotzer C.J., Adams J.L., Lee J.C., Webb E.F., Carpenter D.C., Bochnowicz S., Thomas H.C., Hay D.W.P., Griswold D.E. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Ther. 293:2000;281-288.